SCHEMBL4110177

SCHEMBL4110177

Cc1ccc2cc(NC(=O)Nc3ccc(OC(F)F)cc3)ccc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.52
RAB9A P51151 6/20 0.52
KMT2A Q03164 7/20 0.52
MEN1 O00255 6/20 0.52
MAPT P10636 5/20 0.52
LMNA P02545 2/20 0.52
HTT P42858 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
POLB P06746 3/20 0.50
KDM4E B2RXH2 2/20 0.49
MAPK1 P28482 2/20 0.47
IGF1R P08069 1/20 0.46
PTPN7 P35236 1/20 0.45
RECQL P46063 1/20 0.45
DUSP3 P51452 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MMP1 P03956 1/20 0.45
MMP9 P14780 1/20 0.45
ALOX15 P16050 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4107193 0.89 MAPT (0.53) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL8355880 0.84 NPC1 (0.68) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL4112788 0.81 NPC1 (0.71) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL4107399 0.79 POLB (0.64) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL4118526 0.78 MAPT (0.66) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL4112339 0.78 MAPT (0.60) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL4124128 0.78 RAB9A (0.72) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL24894010 0.77 NPC1 (0.63) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL4116166 0.77 MAPT (0.58) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL4126159 0.77 POLB (0.55) NPC1RAB9AKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 NPC1 927/4885RAB9A 815/4885KMT2A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.